Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer

Table 2

Multivariate analysis of BCR-free survival for all PCa patients.

Comparison	value	Hazard ratio for recurrence	95% CI
Lymph node status	0.904	0.939	0.335, 2.629
FOXO1 expression	0.027	1.390	0.675, 4.095
Gleason score	0.056	0.361	0.122, 1.068
Pathological stage	0.073	0.278	0.059, 1.298
Age	0.806	0.895	0.368, 2.174
Preoperation PSA	0.376	0.644	0.244, 1.704